Public Release: 

New report prescribes recommendations to Congress to restore US leadership in global health

Recent budget constraints put global health scientific advances and product development at risk


The ceasefire in budget battles on Capitol Hill is good news for global health, but is the budget deal made by policymakers enough to handle the surplus of diseases in need of US investments and leadership? That's one question that will be answered in a new report to be released at a briefing on Capitol Hill. The report will highlight the cumulative effect of budget constraints on the fight against threats like AIDS, tuberculosis (TB), malaria, and other diseases that disproportionally affect the developing world. It will include specific recommendations for the US government to strengthen its legacy in global health research. At the event, a panel of global health leaders will offer a frank assessment of whether the US can maintain its lead in the fight against infectious diseases.

US support has been essential to preventing and treating diseases that continue to burden a large portion of the world's population. Among other things, it helped drive the development of the first effective treatments against HIV/AIDS, a vaccine for meningitis A, and a rapid test for detecting tuberculosis. And US investments have helped move scientists close to critical breakthroughs, such as new drugs for TB and malaria; a microbicide that could protect millions of women from HIV; and new insecticides to prevent the spread of diseases like dengue fever, Chagas, and other neglected tropical diseases.

The Global Health Technologies Coalition, a coalition of nearly 30 influential organizations--including groups that develop vaccines, drugs, and other global health tools and technologies--is concerned that US investments have been faltering, just as many of these lifesaving tools appear to be approaching the finish line. They suggest that, as the world's largest player in global health R&D, US policymakers should ensure that the US keeps its edge in global health research by strongly supporting funding and policies to create new tools that save lives.


  • Mr. Steve Davis, President & CEO, PATH (moderator)
  • Dr. Dan Hartman, Director of Integrated Development, Bill & Melinda Gates Foundation
  • Ms. Wendy Taylor, Director of the Center for Accelerating Innovation and Impact, US Agency for International Development (USAID)
  • Mr. Winfred Amoako, TB Survivor

WHEN: Thursday, March 27, 2014 from NOON to 1:30 p.m.
Kennedy Caucus Room (SR 325), Russell Senate Office Building, Washington, DC

RSVP: For more information or to attend in person, contact Katy Lenard at or +1 301-280-5719


About the Global Health Technologies Coalition

The Global Health Technologies Coalition (GHTC) is a group of more than 30 nonprofit organizations working to increase awareness of the urgent need for technologies that save lives in the developing world. These tools include new vaccines, drugs, microbicides, diagnostics, devices, and other products. The coalition advocates for increased and effective use of public resources, incentives to encourage private sector investment, and streamlined regulatory processes. The GHTC is housed at PATH and funded in part by the Bill & Melinda Gates Foundation.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.